


## Market Analysis- Cognitive Science 2020

Alexander Birbrair

As per the most recent study by WHO, it is revealed that [Neurological Disorders](#) including [Stroke](#), [Alzheimer](#) and [Dementia](#), [Epilepsy](#) and a greater number of records for over 12% of deaths worldwide on a normal and it is also predicted that the number of disability-adjusted life years vanished due to Neurological disorders are expected to accelerate from 95 million globally in 2015 to 103 million by 2030. Moreover, the overall expense of neurological sequel solitary estimated in 2010 was US\$ 2.5 trillion and it is expected that the worth will spike to over US\$ 6 trillion by 2030.

WHO's recent research also says that people in U.S, Afghanistan and India is reportedly having high risk of [mental disorders](#). It has been stated that nearly 300 billion people in the world is suffered from mental illness. This illness is not taken in account in serious manner and the death rates due to depression, anxiety and stress are increasing nowadays. The growth in the [Psychiatry](#) field is significant in recent times. The country which tops the research in this field are USA, Europe, Oceania and East Asia.

Market Capitalization of [Neuroscience](#) and [Neuroimmunology](#) companies in 2014 investors provided \$3.3 billion into firms that are developing drugs for neurodegenerative or psychiatric illnesses. In 2016, the worldwide market for neuroscience was valued at around USD 26,350 million and is anticipated to reach around USD 34,800 million by 2024. Between 2017 and 2024, the worldwide neuroscience market is anticipated to show a CAGR



of over 3.5 percent.

The worldwide market size of neuroscience in 2017 was estimated at US\$ 26,593 million and is anticipated to see a CAGR of 3.9 per cent over the forecast era (2018 – 2026) Increasing neurological disease burden globally is anticipated to be a significant factor accelerating the development of the global market for neuroscience. Increasing incidence of malicious diseases including Parkinson's and Alzheimer's disease along with other hereditary CNS disorders has led in enhanced necessity for new neuroscience sector improvements. Due to increasing demand in labs and academic centres, the market is anticipated to grow over the forecast era. Market players strive to introduce distinctive techniques capable of gaining insights to better comprehend compound nervous functionalities and neural manipulations. In addition, growing aggregate geriatric population is expected to considerably drive demand due to a growing need for better therapy and medication.

[Cognitive neuroscience](#) is the scientific field that is concerned with the study of the biological processes and aspects that underlie cognition, with a specific focus on the neural connections in the brain which are involved in mental processes.

[Neurocognitive disorders](#) are characterized by decline from an attained level of cognitive functioning mainly when physical changes can be seen to have occurred in brain, such as after neurological and mental illness, drug use, or brain injury. Neurocognitive disorders (NCDs) are a category of conditions that include [dementia](#), [amnesia](#), [Alzheimer's disease](#), [Mild cognitive impairment](#), [Attention deficit hyperactive disorder](#), [Hallucinogen persisting perception disorder](#), [cerebellar cognitive affective syndrome](#), [post-operative cognitive dysfunction](#), [HIV associated neurocognitive disorder](#).

Alzheimer's disease is the most common form of dementia accounting for 50% to 70% of all cases. It mostly occurs in the older people who are 65 years and above. Moreover, growing awareness level regarding its symptoms, such as partial dementia, is projected to boost the demand. Currently, there are an estimated 4 million individuals with dementia in the USA with more than 100 000 deaths annually. The global market for Alzheimer's disease reached \$10.2 billion in 2012. The market is expected to decrease to \$9.5 billion in 2017 for a CAGR of -1.5%.

The Alzheimer's Association funds independent investigators worldwide, they have awarded over \$335 million to more than 2,250 projects. The global cost of Alzheimer's and dementia is estimated to be \$605 billion, which is equivalent to 1% of the entire world's gross domestic product.

Alexander Birbrair

Professor, Department of Pathology, Federal University of Minas Gerais Brazil , E-mail: alexbirb@gmail.com

## Alexander Birbrair

Aggregate Cost of Care by Payer for Americans Age 65 and Older with Alzheimer's Disease and Other Dementias: Medicare \$113 Billion, Medicaid \$41 Billion, Out of pocket \$44 Billion, Other \$29 Billion.

Dementia is widely considered the second most common cause of dementia after Alzheimer's disease, accounting for 10 percent of cases. Many experts believe that vascular dementia remains underdiagnosed like Alzheimer's disease even though it's recognized as common. The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach \$11.1 billion in 2012. Total market value is expected to reach \$16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.